Usana Health Sciences chief legal officer sells $186,513 in stock

Salt Lake City, UT—Joshua Foukas, the Chief Legal Officer of USANA Health Sciences Inc . (NYSE:USNA), recently sold 5,732 shares of the company’s common stock. The transaction, which took place on March 12, 2025, was executed at a weighted average price of $32.539 per share, resulting in a total sale value of $186,513. The prices during these transactions ranged from $32.50 to $32.60 per share. Following this sale, Foukas no longer holds any shares of USANA Health Sciences.The sale comes as USANA maintains strong fundamentals, with an impressive 81% gross margin and a healthy P/E ratio of 14.4x. According to InvestingPro analysis, the company appears undervalued at current levels, supported by its robust financial health score and strong balance sheet metrics. For deeper insights into insider transactions and comprehensive analysis of USANA’s valuation, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.

In other recent news, USANA Health Sciences reported its fourth-quarter 2024 earnings, exceeding analyst expectations with an earnings per share (EPS) of $0.64, surpassing the forecasted $0.49. The company also reported revenue of $214 million, beating the anticipated $208.84 million. Despite this strong performance, USANA’s guidance for fiscal year 2025 did not meet investor expectations, with projected earnings per share ranging from $2.35 to $3.00, below the consensus estimate of $2.87. The revenue forecast of $920-1000 million for FY2025 also merely bracketed the consensus estimate of $934.5 million.

The company’s acquisition of Hiya Health, aimed at expanding its presence in the children’s health market, contributed minimally to the Q4 results but is expected to significantly impact future earnings. USANA anticipates Hiya’s revenue to grow by 29-42%, reaching between $145 and $160 million in 2025. Analysts from firms such as Sidoti and Company and D.A. Davidson raised questions about USANA’s promotional strategies and the integration of Hiya Health during the earnings call.

USANA’s leadership, including CEO Jim Brown and CFO Doug Hekking, highlighted the company’s focus on launching over 20 new products in 2025 and implementing a new associate incentive program to enhance its direct selling model. The company ended the year with $182 million in cash reserves and plans to increase this by $50-$60 million in 2025. Despite challenges in key markets like China, USANA’s strategic initiatives and financial management indicate a commitment to long-term growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.